13D Filing: James E. Flynn and Alpine Immune Sciences Inc. (ALPN)

Page 11 of 13

Page 11 of 13 – SEC Filing

Page 11 of 13

Item 7. Material to be Filed as Exhibits

Item 7 of the Schedule 13D is hereby
amended by adding the following
:

Exhibit 99.2 Power of Attorney (incorporated by reference to Exhibit 24 to the Form 3 with
regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special
Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III,
L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield
Management Company, L.P., and James E. Flynn).

Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)

Page 11 of 13